Review Papers Claim by Claim

Central claim & verdict

The authors report a practical workflow that converts otherwise “non-assembling” HIV-2 CA into pelleting, EM-observable capsid-like assemblies by switching the inducer from NaCl to potassium glutamate (KGlu), with IP6 enhancing efficiency and pH shifting morphology (more curved/smaller at lower pH; more tubular/extended at higher pH). Core assembly workflow and condition-dependent morphologies

They then test interface logic by mutating divergent HIV-2 residues to HIV-1 equivalents (and capsomere-destabilizing “one-form” disruption designs). Assembly kinetics and morphology shift as predicted for capsomere-specific stability effects, although multiple phenotypes still show residual pleomorphism and occasional amorphous aggregation. Interface mutants and capsomere-bias phenotypes

Decisive evidence (what’s strongest)

• Condition discovery with orthogonal readouts: failure under NaCl with/without IP6, but rapid KGlu-driven turbidity, pelleting, and ordered features by EM (including cryo-EM for representative assemblies). KGlu unlocks assembly; EM supports order
• Quantification strategy explicitly acknowledges inference limits: particle 2D projection area is used as a proxy for capsomere incorporation trends (twelve pentamers requirement), and morphology is categorized into spheres/cones/open-close nanotubes/sheets. EM quantification method and proxy rationale
• Mechanistic plausibility tied to known capsid assembly cofactors: IP6 is presented as a central assembly cofactor for HIV-1, providing a mechanistic basis for testing IP6 dependence here. IP6 as assembly cofactor (HIV-1 precedent)

Limitations / alternatives (tight and evidence-based)

• 2D EM metrics & grid deposition bias: the paper states turbidity/sedimentation are insensitive to disorganized amorphous assembly and that EM quantification is limited by non-random deposition and potential over-interpretation of small differences; classification boundaries (e.g., cone vs nanotube edge cases) can introduce category noise. Stated measurement limitations and cautionary notes
• Strain scope: only HIV-2 GL-AN and HIV-1 NL4-3 are used, so strain diversity effects on the “unique landscape” remain untested. Limited strain diversity as a stated limitation
• In vitro vs in vivo: the authors do not directly validate that these KGlu/IP6/pH-induced morphologies map to cellular assembly dynamics, so causal links to viral fitness/host-factor outcomes remain a hypothesis rather than a demonstrated equivalence. In vitro scope without in vivo equivalence testing

Practical implications (for future mechanistic work)

The work most immediately improves experimental accessibility to HIV-2 CA assemblies—enabling systematic biochemical testing of mutants and interface logic under a defined buffer regime—while also suggesting that “anion identity + pH” may be first-order control parameters for pleomorphism. Tool enabling and key control parameters (anion/pH)